Search results for:

verapamil

verapamil
  • Restricted Medications IV
Brand names: Calan, Calan SR, Isoptin SR
Form Strength
SOLUTION, INTRAVENOUS 5 mg/2 mL
TABLET, EXTENDED RELEASE, ORAL 120 mg/12 hours; 180 mg/12 hours
TABLET, ORAL 80 mg
Display Class IV Antiarrhythmics, Calcium-Channel Blocking Agents Class: 24040424, 242800
Medication comments:
verapamil should generally not be interrupted during procedures unless there is a specific physician order.

Calcium Channel Blockers (non-dihydropyridine) require the following prior to each administered dose:
1) Nursing staff shall obtain the patient’s pulse and record in the EMR.
2) If the pulse is less than 50, the nurse shall obtain an apical heart rate. If the apical heart rate is less than 50, the nurse shall hold the dose and notify the provider for further orders.
3) This is applicable to all routes of administration
Per policy, these medications require cardiac and/or special monitoring.
(KEY: "Y" = may be given as described on chart. "N" = may NOT be given except in Rapid Response/Code Blue situations or as otherwise described in Exceptions section of Policy.
generic (Brand) / Notes CCU, OR, PACU, CCL, ED PCU 2N (Tele) 1N (Tele), 3N (Tele) Med/Surg (1N w/o Tele, 3N w/o Tele, 4N, 5N) BirthPlace SNF ICS OPS
verapamil (Calan, Isoptin)
IV Push		 Y N N N N Y
with RESP standby		 N N N
Enteral Drug Administration notes.
Generic
(Brand)		 Comments and Considerations Recommendations for Administration with Enteral Nutrition
verapamil
(Isoptin, Calan,Verelan)		 May open Verelan capsule but do NOT crush the contents Verelan capsule may be opened contents may be emptied into feeding tube, but do NOT crush contents.
2023 American Geriatrics Society Beers Criteria® for potentially inappropriate medication use in older adults.
Medication: verapamil (Calan, Covera, Isoptin)
Criteria 2: Potentially inappropriate medication use in older adults due to drug–disease or drug–syndrome interactions that may exacerbate the disease or syndrome. (Table 3)
Drug(s) ⇆ disease or syndrome non-dihydropyridine calcium channel blockers (CCBs) ⇄ Heart failure
Rationale Potential to promote fluid retention and/or exacerbate heart failure.
Recommendation Avoid in heart failure with reduced ejection fraction.
 Quality of evidence: Moderate, Strength of Recommendation: Strong
Pediatric Pharmacy Association 2025 KIDs List of Key Potentially Inappropriate Drugs in Pediatrics 
Medication: verapamil (Calan, Covera, Isoptin)
Key Potentially Inappropriate Drugs in Pediatrics (KIDs) List: Second Edition (Table 1)
Drug verapamil
Risk/Rationale Cardiovascular collapse
Recommendation Caution in younger than 1 yr
 Quality of evidence: Low, Strength of Recommendation: Weak
Last updated: Mar. 14, 2026
UpToDate Lexidrug

Pharmacy Contact Info:

Main Inpatient Pharmacy: ext 4599, 3503
Fax: 704-878-7283

Director of Pharmacy - Randi Raynor, PharmD: ext 4501
Clinical Coordinator - Laura Rollings, PharmD: ext 4597
Pharmacy Informaticist - Stephen Pringle, PharmD: ext 7645
Pharmacy Technician Supervisor - Amy Wingler, CPhT: ext 7385
Pharmacy Automation Coordinator (Omnicell) - Melissa Fulford, CPhT: ext 3556



This site is intended for the staff of Iredell Health System. While others may view accessible pages, Iredell Health System makes no warranty, express or implied, as to the use of this information outside of Iredell Health System. The content of this policy and procedure document serves as guidance to the delivery of quality patient care. Care providers are expected to exercise critical thinking and situational awareness skills, and in specific situations to take such action as is necessary for the delivery of quality patient care.
Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved